Biotechnology - Licensing

Filter

Current filters:

Licensing

Popular Filters

1 to 25 of 375 results

Shire in strategic collaboration with ArmaGen for Hunter syndrome

Shire in strategic collaboration with ArmaGen for Hunter syndrome

23-07-2014

Ireland-headquartered drugmaker Shire has entered into an agreement with US privately held biotech company…

AGT-182ArmagenBiotechnologyCNS DiseasesHunter syndromeIrelandLicensingShireUSA

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

23-07-2014

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours…

BiotechnologyLicensingneratinibOncologyPB272PfizerPuma BiotechResearchTrastuzumabUSA

Zeltia diversifying its business pharma model to finance R&D pipeline

22-07-2014

PharmaMar, biopharmaceutical company which represents the main affiliate of Spanish Grupo Zeltia is diversifying…

AplidinBiotechnologyChugai PharmaceuticalGP PharmLicensingOncologyPharmaMarPM 1183PolitrateResearchZeltia

PharmaMar and Chugai link up to commercialize Aplidin in Europe

17-07-2014

Spanish drugmaker Zeltia, through its biotech subsidiary PharmaMar, and Japan’s Chugai Pharmaceutical…

AplidinBiotechnologyChugai PharmaceuticalEuropeLicensingOncologyPharmaMarplitidepsinZeltia

Immunocore and Eli Lilly sign $25 million collaboration

Immunocore and Eli Lilly sign $25 million collaboration

16-07-2014

UK-based biotech firm Immunocore and US drug major Eli Lilly today announced they have entered into a…

BiotechnologyEli LillyImmunocoreImmunologyLicensingLillyOncologyUKUSA

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

14-07-2014

Anglo-Swedish drug major AstraZeneca’s recent $230 million deal with British respiratory drug development…

AsthmaAstraZenecaBiotechnologyInterferonLicensingRespiratory and PulmonaryRespiratory therapySNG001SynairgenUK

BIND Thera and Amgen end their Accurin collaboration

BIND Thera and Amgen end their Accurin collaboration

03-07-2014

US clinical stage drug developer BIND Therapeutics saw its shares plunge 15.8% to $10.84 in after-hours…

AccurinsAmgenBIND TherapeuticsBiotechnologyLicensingOncology

Debiopharm signs deal with Nobelex Biotech over antibiotics

Debiopharm signs deal with Nobelex Biotech over antibiotics

27-06-2014

Swiss pharma company Debiopharm Group and Canadian biotech company Nobelex Biotech have announced a collaboration…

Antibiotics and Infectious diseasesBiotechnologyCanadaDebiopharmLicensingNobelex Biotech

Merck & Co in new accord with Bionomics for CNS research

Merck & Co in new accord with Bionomics for CNS research

24-06-2014

Australian biotech firm Bionomics has entered into a second exclusive research collaboration and license…

BionomicsBiotechnologyBNC375LicensingMerck & CoNeurologicalResearch

Bayer strikes deal with Dimension Therapeutics to develop hemophilia A gene therapy

23-06-2014

USA-based venture capital;-backed biotech Dimension Therapeutics has entered into a collaboration with…

BayerBiotechnologyDimension TheapeuticsHematologyLicensingResearch

BIND Therapeutics and Roche collaborate on discovery of novel nanomedicines

BIND Therapeutics and Roche collaborate on discovery of novel nanomedicines

19-06-2014

US clinical stage, investor backed biopharma company BIND Therapeutics (Nasdaq: BIND) has entered into…

BIND TherapeuticsBiotechnologyLicensingResearchRoche

Vertex licenses novel influenza treatment VX-787 to Janssen

Vertex licenses novel influenza treatment VX-787 to Janssen

18-06-2014

US biotech firm Vertex Pharmaceuticals has inked a deal with health care giant Johnson & Johnson subsidiary…

Anti-viralsBiotechnologyGlobalHealth Medical PharmaJanssenJohnson & JohnsonLicensingVertex PharmaceuticalsVX-787

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

18-06-2014

China-based biotech firm 3SBio has entered into an exclusive license with Selecta Biosciences for pegsiticase…

3SBioAnti-Arthritics/RheumaticsBiotechnologyLicensingpegsiticaseSelecta Biosciences

Celgene exercises option for Agios Pharma’s AG-221

Celgene exercises option for Agios Pharma’s AG-221

17-06-2014

Metabolism specialist Agios Pharmaceuticals says that its partner, biotech major Celgene Corp, has exercised…

AG-221Agios PharmaceuticalsBiotechnologyCelgeneLicensingOncologyRegulationResearchUSA

Takeda to withdraw NDA as Omontys pact with Affymax ends

Takeda to withdraw NDA as Omontys pact with Affymax ends

15-06-2014

USA-based Affymax and Japan's Takeda Pharmaceutical revealed on Friday that they have terminated their…

AffymaxBiotechnologyLicensingOmontysOncologyRegulationTakeda Pharmaceutical

ScinoPharm to provide API for TaiGen’s novel stem cell drug burixafor

ScinoPharm to provide API for TaiGen’s novel stem cell drug burixafor

11-06-2014

Taiwanese drugmaker ScinoPharm Taiwan and Taiwan-based drug developer TaiGen Biotechnology have signed…

BiotechnologyLicensingOncologyProduction

Israel’s OphthaliX updates on clinical developments and strategic plans

09-06-2014

Israel-based OphthaliX, a majority-owned subsidiary of biotech firm Can-Fite BioPharma focussed on ophthalmic…

BiotechnologyCan-Fite BioPharmaLicensingOphthaliXOphthalmicsResearch

UK life sciences meeting agrees adaptive licensing is a golden opportunity

UK life sciences meeting agrees adaptive licensing is a golden opportunity

03-06-2014

Adaptive licensing is a “golden opportunity” to demonstrate the strength of life sciences in the…

Association of the British Pharmaceutical IndustryBiotechnologyLicensingPharmaceutical sciencesUK

GlaxoSmithKline surprises with mega-dollar deal for cancer program

GlaxoSmithKline surprises with mega-dollar deal for cancer program

02-06-2014

UK biotech firm Adaptimmune revealed this morning that it has entered into a collaboration and licensing…

AdaptimmuneBiotechnologyGlaxoSmithKlineLicensingOncologyResearch

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

30-05-2014

US biotech firms Array BioPharma and Biogen Idec have entered into a collaboration for the discovery…

Array BioPharmaBiogen IdecBiotechnologyImmunologicalsLicensingResearch

uniQure signs up Medison to distribute Glybera in Israel

uniQure signs up Medison to distribute Glybera in Israel

29-05-2014

Netherlands-based human gene therapy firm uniQure has entered an exclusive distribution agreement with…

BiotechnologyGlyberaLicensingMedison PharmaRare diseasesRest of the WorlduniQure

MacroGenics and Takeda link up to develop DART for autoimmune disorders

27-05-2014

Privately held US biotech firm MacroGenics and Japan’s largest drugmaker Takeda Pharmaceutical have…

BiotechnologyImmunologicalsLicensingMacroGenicsMGD010Takeda Pharmaceutical

1 to 25 of 375 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top